Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Single-Centre, Randomised, Single-dose, Open-label, 2-period, 2-way Crossover Study to Assess the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin in Participants With Kidney Failure

NCT07754331 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07754331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07754331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Single-Centre, Randomised, Single-dose, Open-label, 2-period, 2-way Crossover Study to Assess the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin in Participants With Kidney Failure
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Recruiting
Start date
August 6, 2026
Completion date
December 3, 2026
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney failure